ArticleEuropean urology focus2026

Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).

Susan Halabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.